An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

Trial Profile

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Acamprosate (Primary)
  • Indications Anxiety disorders; Generalised anxiety disorder; Panic disorder; Post-traumatic stress disorders; Social phobia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Planned end date (Jan 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top